# ðŸ“£ Updates {transition="slide-in none"}

## ðŸ— Key Policy Updates!

> If nothing else, take this home!

- The FDA appears to accept `.R` files through their eSUB portal[^1].
- The FDA has released a draft of a new _Computer Software Assurance[^2]_ guideline
  that seems to be increasingly the basis for their evaluation of R.

[^1]: [R Consortium R Submission WG, Pilot #1](https://github.com/RConsortium/submissions-pilot1)
[^2]: [_Computer Software Assurance for Production and Quality Systems Software: Draft Guidance for Industry and Food and Drug Administration Staff_](https://www.fda.gov/media/161521/download)

## ðŸ— Key Policy Updates!

> If nothing else, take this home!

::: {.callout-tip}
## Identifying Intended Use [^2]

Software is used **directly** for the production and quality systems' 
automation inspection, testing, or the collection and processing of 
production data. Software **supports** development, monitoring and 
automated testing. _A manufacturer_ should use a **risk-based analysis
to determine appropriate assurance activities.**
:::

## ðŸ— Key Policy Updates!

> If nothing else, take this home!

::: {.callout-tip}
## Determining the Appropriate Assurance Activities[^2]

Assurance can include _Ad-hoc testing_, _Exploratory testing_ (active package use), 
_Error-guessing_ (regression testing), 
_Robust scripted testing_ and _Limited scripted testing_ (traceable, reproducible testing suites).

"This approach may apply scripted testing for high-risk features"
:::

## Change of Leadership

- We thank Andy for his leadership and enthusiasm that brought the R Validation Hub to this point.
- New R validation hub lead is Doug Kelkhoff

### Pulse Check

<!-- - We looked back on how we had been working -->
- Identified new opportunities
  1. Refining holistic strategic direction
  1. Be mindful about communication and organization
- We have a new Communication workstream! (and awesome new slides!)
- More ways to get involved

# ðŸ“œ Workstream Report

## [Case Studies](https://www.pharmar.org/casestudies/)

> 7 Companies Shared their Approach to Package Validation

:::: {.columns style="font-size: 0.7em;"}
::: {.column width="33%"}
#### Commonalities

- Categorized risk (hi/med/lo)
- Heavily weight unit testing
- Base & Suggested packages "trusted"
:::

::: {.column width="33%"}
#### Differences

- Risk stratification (eg coverage cutoff)
- Managing risk
  - human-in-the-middle review 
  - restricted package subset
  - adding bespoke testing
:::

::: {.column width="33%"}
#### Themes

- Time & resource intensive
- Requires unique intersection of expertise
- **Challenges of lifecycle management of ecosystem**
:::
::::


## ![](assets/riskmetric.png){height="1.8em" width="1.8em" style="margin: 0 0.2em; object-fit: contain;vertical-align: middle;"} `{riskmetric}` Roadmap

::: { style="font-size:0.8em" }
- **Ease of use:**  
  Wrapper functions for a a complete workflow, prettier outputs
- **Metric completeness:**  
  Implement metrics for as many pacakge sources as possible. Chain sources 
  together to create more complete assessments
- **Modular addititions:**  
  Allow users to easy add custom assessments, create optional assessments 
  based on community packages (e.g. `oyster`, `srr`, `pkgstats`, etc)
- **Focusing on metrics and scoring:**  
  Making custom weighting more robust and convenient. Guidance materials on 
  weighting specific assessments based on community feedback and our own views 
  on best practices.
:::


## ![](assets/riskassessment.png){height="1.8em" width="1.8em" style="margin: 0 0.2em; object-fit: contain;vertical-align: middle;"} `{riskassessment}` App

### Feature Recap

- Face lifts for _Report Builder_ & _Database View_
- Better dependency inspection
- Org-level customizations using config file
- Allow `admin` user role management
- Package file explorer

## ![](assets/riskassessment.png){height="1.8em" width="1.8em" style="margin: 0 0.2em; object-fit: contain;vertical-align: middle;"} `{riskassessment}` App

#### New Test explorer! (Code provided by _GSK_)

![](assets/riskassessment-file-browser.png){.r-stretch .center style="display: block; margin: auto;"}


# ðŸ“¦ Repositories

## Repositories Workstream

::: { style="font-size: 0.8em;" }
> Supporting a transparent, open, dynamic, cross-industry approach of
> establishing and maintaining a _repository_ of R packages.

* Taking ample time to engage stakeholders
  * Validation leads across the industry
  * Active health authority involvement
  * Analytic environment admins and developers
* Considering the possibilities
  * Mapping needs to solutions that meet the industry where it is
  * ...while building the path for it to move forward
:::


## How did we get here?

::: {.incremental style="font-size: 0.8em;"}
* [Our whitepaper is widely adopted]{.fragment .semi-fade-out}
* [But implementing it is inconsistent & laborious]{.fragment .semi-fade-out}   
  * [Variations throughout industry pose uncertainty]{.fragment .semi-fade-out}
  * [Sharing software with health authorities is a challenge]{.fragment .semi-fade-out}
  * [Health authorities, overwhelmed by technical inconsistencies, are more likely to question software use]{.fragment .semi-fade-out}
* We feel the most productive path forward is a shared ecosystem
:::

::: {.notes}
- **inconsistent**: Vendored choices inevitably face inconsistency when
  merged with internally developed tools
- **sharing**: `pkglite`, `.R` files now permitted, Hosting on git repo/r-universe? But comes with extra install steps.
- **laborious**: We're all reviewing the same tools, duplicating effort and
:::


## Work to-date

**Building consensus in package evaluation and distribution...**

0. Who needs a repository anyways?
1. Stakeholder engagement [3mo]{.dim}  
2. Product refinement and proof-of-concept planning [1mo]{.dim}
3. POC development [2mo]{.dim}


## âœ‹ Hold up! Why a repository?

> "Every successful team starts with a small existential crisis"  
>  -- _unknown_

- Tools for building evaluation in-house?
- Sharing of extra testing resources?
- Curation of packages?
- A stricter CRAN?


## Embracing change

:::: {.fragment}
### Old dog, new trick

::: {.inremental style="font-size: 0.8em;"}
* Modern package ecosystems are the stats world's _new trick_
* Methods are provided directly by statisticians and academics, rarely by vendors.
* Risk is managed not by itemized requirements, but by good development practices.[^2]
* We need to learn how to manage risk in a constantly evolving ecosystem
:::

[^2]: [_Computer Software Assurance for Production and Quality Systems Software: Draft Guidance for Industry and Food and Drug Administration Staff_](https://www.fda.gov/media/161521/download)

::: {.notes}
- **evolving**: 
  - Patches constantly fixing edge cases. Neglect to update is a risk.
  - Health authorities use latest CRAN. Differences
    in their system and yours introduces risk of inconsistency in results.
:::
::::


## Comparing Approaches

```{=html}
<style>
.dense-list ul, .dense-list li {
  margin-top: 0.1em !important;      
  margin-bottom: 0.1em !important;
}
</style>
```

::::: {style="font-size: 0.7em;"}
:::: {.columns .dense-list}
::: {.column width="50%"}
##### Vendored Stats Products
:::
::: {.column width="50%"}
##### Data Science Ecosystem
:::
::::

:::: {.columns .dense-list .fragment}
::: {.column width="50%"}
* Of-the-shelf [**cohort**]{style="color: green;"}.
:::
::: {.column width="50%"}
* A "snapshot" of [**living repository**]{style="color: green"}.
:::
::::

:::: {.columns .dense-list .fragment}
::: {.column width="50%"}
* Internal tools developed [**against cohort**]{style="color: color-mix(in lch, green 80%, red)"} 
  packages.
:::
::: {.column width="50%"}
* Internal tools developed [**against latest**]{style="color: green;"} 
  packages.
:::
::::

:::: {.columns .dense-list .fragment}
::: {.column width="50%"}
* New package versions [**risk incompatibility**]{style="color: color-mix(in lch, green 60%, red)"}.
:::
::: {.column width="50%"}
* New packages can be [**reviewed and upgraded at-will**]{style="color: green;"}.
:::
::::

:::: {.columns .dense-list .fragment}
::: {.column width="50%"}
* Steep [**upgrade cost (time, developement)**]{style="color: color-mix(in lch, green 40%, red)"}.
:::
::: {.column width="50%"}
* Living ecosystem, constantly [**vetted against new releases**]{style="color: green;"}
:::
::::

:::: {.columns .dense-list .fragment}
::: {.column width="50%"}
* [**System-specific mix of packages**]{style="color: color-mix(in lch, green 20%, red)"}.
:::
::: {.column width="50%"}
* [**More likely what is used by HAs**]{style="color: green;"}
:::
::::

:::: {.columns .dense-list .fragment}
::: {.column width="50%"}
* [**Tied to current validation expectations**]{style="color: color-mix(in lch, green 10%, red)"}.
:::
::: {.column width="50%"}
* [**Adaptable as R best practices evolve**]{style="color: green;"}
:::
::::

:::: {.center .dense-list .fragment style="margin: auto;"}
[**Challenges shipping in-house code**]{style="color: color-mix(in lch, green 10%, red)"}.
::::
:::::


## Interesting Stakeholder Findings

- Health authority primary concerns
  - Avoiding **security vulnerabilities** while using R
  - Visible discussions **vetting methodology** and relevance
- Industry validation leads
  - Relieved that open-source tools are public, less need to audit
    vendored tools
- System administrators, users and developers
  - Want **clarity** and **consistency** internally and externally


## Prototyping

Running three prototypes to explore specific needs

- Test case exchange format ([repo](https://github.com/kkmann/rmes/pulls))
- Communication channels for methods discussion & considerations ([google doc](https://docs.google.com/presentation/d/1b9VZjVM1pzzSmrO7WFKK43EjBZMT0smRrNY_0BPSR0s/edit#slide=id.g1e4f3a104ee_0_0))
- Risk filters and transparency of known vulnerabilities ([repo](https://github.com/dgkf/rvalhub-repo-filters-mvp))


## Prototyping
### Test Case Exchange Format

```json
{
  "rPackage": {
    "name": "stats",
    "link": "https://cran.r-project.org/package=stats"
  },
  "CSADocPkg": {
    "function": {
      "name": "t.test",
      "assuranceActivity": {
        "activityType": "Scripted Testing: Robust",
        "definition": "Scripted testing efforts in which the risk of the computer system or automation includes evidence of repeatability, traceability to requirements, and auditability.",
        "parameters": {
          "testObjectives": [
            {
              "uuid": "6cde1b0f-3e41-4878-8cd5-79c87be88a7d",
              "objective": "Verify that p values produced by stats::t.test are uniformly distributed",
              "keywords": ["t.test", "p values", "uniform distribution"],
              "testCases": [
                {
                  "uuid": "4fa03a8d-2e39-4866-9cd3-69b77bd78a6b",
                  "testName": "t test produces calibrated p values",
                  "description": "This test checks that the p values produced by stats::t.test do not deviate substantially from the expected uniform distribution.",
                  "code": "set.seed(42)\\nm <- 100\\nfor (n in c(5, 50, 500)) {\\n# repeatedly sample data under null and record p value\\nres <- numeric(m)\\nfor (i in 1:m) {\\nres[i] <- t.test(rnorm(n))$p.value\\n}\\n# expect non significant result\\nexpect_true(\\nks.test(res, 'punif')$p.value > 0.05\\n)\\n}",
                  "result": "pass",
                  "environment": {
                    "container": "rocker/tidyverse:4.3.1",
                    "runtime": "singularity",
                    "runtimeVersion": "3.8",
                    "renvLockfile": ""
                  }
                }
  ...
```

## Prototyping 
### Communication Channels

![](assets/rvalhub-comm-channels.svg)


## Prototyping 
### Package Security & Risk Filters

```r
install.packages("options")
#> Security vulnerabilities found in packages to be installed.
#> To proceed with installation, re-run with `accept_vulnerabilities = TRUE`
#> 
#> â”€â”€ Vulnerability overview â”€â”€
#> 
#> â„¹ 1 package was scanned
#> â„¹ 1 package was found in the Sonatype database
#> â„¹ 1 package had known vulnerability
#> â„¹ A total of 1 known vulnerability was identified
#> â„¹ See https://github.com/sonatype-nexus-community/oysteR/ for details.
```

```r
nrow(available.packages())
#> 5 "low risk" packages

options(available_packages_filters = NULL)
nrow(available.packages())
#> 17 available packages
```


## A fork in the road

Given the key capabilities and tools to address them. How do we bundle
these solution to address industry needs?

:::: {.columns style="font-size: 0.7em;"}
::: {.column .fragment width="50%"}
**Support our industry today**

> _Delivering in-house solutions for you to pick-and-choose_

- Consistent processes to apply
- Local tools to deploy in-house
- Community forum for knowledge sharing
:::

::: {.column .fragment width="50%"}
**Build what we want the industry to be**

> _Drive change through transparency and consistency_

- Lead by example with a public solution
- Make it easier to adopt than re-build
- Transparency-first solutions
:::
::::


## What does a solution look like? {visibility="hidden"}

::: {.callout-note}
## If it's not broke, don't fix it!
:::

::: {.incremental style="font-size: 0.8em;"}
- R has this wonderful thing called CRAN, setting the standard of quality
  - Packages are constantly tested together
  - R has a culture of amazing documentation
  - Statisticians flock to R, and are constantly vetting its implementations
:::


## What does a solution look like? {visibility="hidden"}
::: {.callout-warning}
## Fool me twice, shame on me
:::

::: {.incremental style="font-size: 0.8em;"}
- R has this thorn in its side called CRAN, 
  - Builds are difficult to reproduce (key for validation)
  - Quality indicators are lacking
  - Difficult to roll back to an older snapshot (although tools exist to help with this.)
  - Governance isn't always the most friendly
:::


## What does a solution look like?

::: {.callout-tip}
## Closing the CRAN gap for the Pharma Use Case
:::

- Reproducibility guidelines
- Standard, public assessment of packages
- Avenues for communicating about implementations, bugs, security


## The Proposal so Far

![](assets/repository-diagram.svg){.r-stretch .center style="display: block; margin: auto"}

## ðŸ§— "Leaps of Faith"

```{=html}
<style>
.highlight {
  color: var(--r-heading-color);
}
</style>
```

- [***A "Golden" Base Image***]{.highlight}  
  to establish ground truth for testing.
- [***Rethinking requirements***]{.highlight}  
  testing, external vetting (CRAN) and adoption are sufficient for _Scripted 
  Testing_ needs - are new requirements necessary?  
- [***Expectations of Public Communication***]{.highlight}  
  industry-standard communication channels.
- [***Nearly all meaningful assessment can be automated***]{.highlight}  
  edge cases (malicious code, methods debate) are better handled by 
  transparent community engagement.

## The Proposal so Far

![](assets/repository-diagram.svg){.r-stretch .center style="display: block; margin: auto"}

## ðŸ§— "Leaps of Faith" Discussion

```{=html}
<style>
.highlight {
  color: var(--r-heading-color);
}
</style>
```

::: {style="font-size: 0.8em"}
> How would your operations change if the industry adopted...

- [***A "Golden" Base Image***]{.highlight}  
  to establish ground truth for testing.
- [***Rethinking requirements***]{.highlight}  
  testing, external vetting (CRAN) and adoption are sufficient for _Scripted 
  Testing_ needs - are new requirements necessary?  
- [***Expectations of Public Communication***]{.highlight}  
  industry-standard communication channels.
- [***Nearly all meaningful assessment can be automated***]{.highlight}  
  edge cases (malicious code, methods debate) are better handled by 
  transparent community engagement.
:::
